Super-Responders to Opicapone Adjunct Treatment to Levodopa in Parkinson’s Disease Patients with Motor Fluctuations: Combined Post-Hoc Analysis of BIPARK-I and II
Objective: To evaluate the efficacy and safety of opicapone (OPC) in Parkinson’s disease (PD) patients who were considered ‘super-responders’ (>= 2 hours of OFF-time reduction…New compound increasing glucocerebrosidase activity on primary cell cultures obtained from patients with GBA-associated Parkinson’s disease
Objective: To determine whether new chemical modifications of the previously described allosteric GCase chaperone N607 (Aflaki E et.al Neurosc. 2016) increase GCase activity in monocyte-derived…Safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, as a function of baseline dyskinesia (BL-dyskinesia) in Parkinson’s disease (PD): A pooled analysis of 4 studies
Objective: To evaluate the effect of BL-dyskinesia on the efficacy and safety of istradefylline in 4 randomized, placebo-controlled, double-blind, phase 2b/3 trials. Background: Istradefylline, a…Positive Correlations Between Quality of Life and Sleep Dysfunction in Advanced Parkinson’s Disease Patients Prior to and After 12 Months of Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis From the DUOGLOBE Study
Objective: To evaluate the relationship between sleep disturbances and quality of life (QoL) in advanced Parkinson’s disease (PD) patients both prior to and at month…Pharmacokinetics of Levodopa in patients with Parkinson’s disease: Efforts toward a predictive model
Objective: Our aim was to explore correlations between the pharmacokinetics of levodopa (LD) and clinical manifestation in patients with Parkinson’s disease (PD). Our goal was…Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Impulse Control Disorders
Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) on impulse control disorders (ICD) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In…Efficacy and Safety of Opicapone in Parkinson’s Disease Patients According to Duration of Motor Fluctuations: Post-Hoc Analysis of BIPARK-I and II
Objective: This exploratory post-hoc analysis evaluated the efficacy and safety of opicapone (OPC) in levodopa-treated Parkinson’s disease (PD) patients with duration of motor fluctuations of…The influence of ANNK1/DRD2 haplotypes on the onset of complications of long-term levodopa therapy in Parkinson’s disease
Objective: To investigate an influence of selected polymorphisms in DRD2 and ANKK1 genes on the occurrence of complications of long-term levodopa therapy in Serbian PD…A Long-Term Safety, Tolerability, and Efficacy Study of Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Interim Results
Objective: Evaluate the long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL-130277; APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s…Opicapone’s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson’s disease: a post-hoc analysis of BIPARK-I and II
Objective: To evaluate opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations according to disease- and therapy-related characteristics. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 32
- Next Page »